Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer Policy Dana-Farber to pay $15M to U.S. government in research fraud settlement December 19, 2025Vol.51 No.46By Jacquelyn Cobb
In Brief Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research October 03, 2025Vol.51 No.36
Clinical Roundup Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows September 12, 2025Vol.51 No.33
Clinical Roundup Peptide drug shows promise in treating glioblastoma, Virginia Tech researchers find June 06, 2025Vol.51 No.22
In Brief Swim Across America grants $900,000 toward gene editing innovation April 25, 2025Vol.51 No.16
In Brief Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber February 21, 2025Vol.51 No.07
Clinical Roundup Cancer vaccine shows promise for patients with stage 3 and 4 kidney cancer February 07, 2025Vol.51 No.05
Clinical Roundup DFCI researchers use PET imaging to detect body inflammation January 24, 2025Vol.51 No.03
